Accelerating CNS Drug Development Using Biomarkers
In this episode of Mind the Methods (the ICTM podcast), Dr. Kemi Olugemo, ISCTM Scientific Committee member and consulting Chief Medical Officer at Junevity, and Dr. Siân Ratcliffe Smethurst, ISCTM President-Elect and Chief Operating Officer of Premier Research, discuss how biomarkers can accelerate CNS drug development without creating false confidence and what practical methods sponsors can use to create regulatory flexibility while preserving scientific rigor.
A biomarker is only useful within a clearly defined context of use. The same measure can support enrichment, target engagement…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.